VCEL Vericel Corp
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 887359 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY25.3%
TTM net income YoY154.6%
TTM EPS YoY146.2%
Revenue 3-yr CAGR20.5%
Net income 3-yr CAGR—
Margins
Gross margin74.5%
Operating margin8.3%
Net margin10.3%
FCF margin17.9%
EBITDA margin12.4%
Returns
ROE9.4%
ROA6.9%
ROIC (approx.)9.0%
Asset turnover0.67x
Leverage & solvency
Liabilities / assets25.7%
Debt / equity0.00x
Current ratio5.13x
Interest coverage42.01x
Cash quality & payout
Operating cash flow / net income1.96x
Accruals ratio-6.6%
Payout ratio—
Capex / revenue2.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $276.26M | $237.22M | $197.52M | $164.37M | $156.18M |
| Cost of revenue | $70.66M | $65.12M | $61.94M | $54.58M | $50.16M |
| Gross profit | $205.60M | $172.11M | $135.58M | $109.79M | $106.03M |
| R&D expense | $27.56M | $24.80M | $21.04M | $19.94M | $16.29M |
| SG&A expense | $166.99M | $142.79M | $121.00M | $106.90M | $97.59M |
| Operating income | $11.04M | $4.52M | -$6.46M | -$17.06M | -$7.85M |
| Interest expense | $630,000 | $614,000 | $600,000 | $366,000 | $4,000 |
| Pretax income | $17.38M | $10.51M | -$2.37M | -$15.99M | -$7.58M |
| Income tax | $859,000 | $148,000 | $814,000 | $721,000 | -$111,000 |
| Net income | $16.52M | $10.36M | -$3.18M | -$16.71M | -$7.47M |
| EBITDA | $22.59M | $10.02M | -$1.83M | -$13.08M | -$4.89M |
| EPS (basic) | 0.33 | 0.21 | -0.07 | -0.35 | -0.16 |
| EPS (diluted) | 0.32 | 0.20 | -0.07 | -0.35 | -0.16 |
| Weighted avg. shares (diluted) | 52.15M | 51.68M | 47.59M | 47.13M | 46.47M |
| Balance sheet | |||||
| Cash & equivalents | $100.09M | $85.05M | $69.09M | $51.07M | $68.54M |
| Short-term investments | $37.41M | $41.69M | $40.47M | $68.47M | $35.07M |
| Receivables | $84.63M | $61.38M | $58.36M | $46.54M | $37.44M |
| Inventory | $17.56M | $17.37M | $13.09M | $15.99M | $13.38M |
| Current assets | $247.44M | $212.78M | $205.63M | $186.87M | $158.46M |
| PP&E, net | $108.40M | $103.16M | $41.63M | $15.84M | $13.31M |
| Intangibles | $5.62M | $6.25M | $6.88M | $7.50M | $0 |
| Total assets | $487.97M | $432.72M | $353.66M | $273.00M | $243.71M |
| Current liabilities | $49.15M | $50.29M | $45.75M | $37.46M | $26.05M |
| Total liabilities | $133.33M | $140.75M | $127.70M | $80.73M | $73.24M |
| Shareholders' equity | $354.64M | $291.97M | $225.95M | $192.27M | $170.46M |
| Shares outstanding | 50.62M | 49.63M | 47.83M | 47.25M | 46.88M |
| Cash flow statement | |||||
| Operating cash flow | $51.91M | $58.16M | $35.31M | $17.69M | $29.04M |
| Capital expenditure | $27.16M | $63.97M | $20.01M | $7.60M | $7.92M |
| Free cash flow | $24.75M | -$5.81M | $15.30M | $10.09M | $21.12M |
| Investing cash flow | -$43.94M | -$79.03M | -$3.13M | -$36.21M | -$3.50M |
| Financing cash flow | $7.07M | $19.05M | $3.62M | $1.04M | $9.17M |
| Depreciation & amortization | $11.54M | $5.50M | $4.63M | $3.98M | $2.96M |
| Stock-based compensation | $38.77M | $36.49M | $32.33M | $37.18M | $34.32M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.